CD274 and neoplasm: Current research is focused on identifying predictive biomarkers (e.g., PD-L1 expression, tumor mutational burden), exploring novel targets (e.g., TIM-3, LAG-3, TIGIT), and developing combination strategies involving chemotherapy, vaccines, or targeted agents [180,181,182].